Funding for this research was provided by:
Fundació la Marató de TV3 (TV3 20131530)
Ministerio de Ciencia, Innovación y Universidades (SAF2017-86117-R, SAF2014-55997-R)
Susan G. Komen (CCR13262449)
Instituto de Salud Carlos III (PI11/00692, PIE13/00022, PI14/00329, PI19/01181)
Breast Cancer Research Foundation (BCRF19-008)
European Research Council (LS4-682935)
Fundación Científica Asociación Española Contra el Cáncer (GCAEC19017ARRI)
Received: 24 April 2020
Accepted: 11 January 2021
First Online: 30 March 2021
Ethics approval and consent to participate
: This work obtained ethics approval to use the human tissue samples by the North West – Greater Manchester Central Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), reference number 15/NW/0685. Informed consent was obtained from all individuals prior to surgery to use their tissue materials in research. This study was performed in compliance with the clinical research guidelines established by the Dr. Josep Trueta University Hospital Ethics Committee. This study was approved by the Institutional Review Board of Hospital Vall d’Hebron (Barcelona) AC/R (AG)110/2013(3755). All patients provided written informed consent.
: Not applicable.
: EGS has served on advisory boards for Amgen and has received research funding from Amgen. AP has declared personal honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly, and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; and research funding from Roche and Novartis; consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer, and Bristol-Myers Squibb. SP has received travel and accommodation grants from Roche and Novartis and holds consulting/advisory roles for Polyphor and Roche.